Literature DB >> 1290164

Thrombosis in spinal cord injury.

Y Fujii1, E F Mammen, A Farag, J Muz, G G Salciccioli, S T Weingarden.   

Abstract

Some traditional coagulation assays and several new molecular markers of hemostatic activation were measured in 37 patients with spinal cord injury (SCI). Twenty one of the patients (57%) developed deep vein thrombosis (DVT). The radiofibrinogen uptake test (RFUT) was used to diagnose DVT. Thirty eight percent of quadriplegic and 88% of paraplegic patients developed DVT (p < 0.005). No significant differences were found in platelet counts, mean platelet volumes, fibrinogen levels, von Willebrand factor (Ag) levels, platelet factor 4 and beta thromboglobulin concentrations between the groups with and without DVT. Fibrinopeptide A, thrombin/antithrombin III (TAT) complexes and plasma D-dimer levels were significantly higher in the patients with thrombosis. Most patients with DVT had elevated TAT complex levels up to three days before the RFUT became positive. D-dimer levels were highest after the diagnosis had been made.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1290164     DOI: 10.1016/0049-3848(92)90094-q

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  10 in total

1.  Changes in von Willebrand factor and fibrinolysis following a post-exercise cool-down.

Authors:  C M Paton; P R Nagelkirk; A M Coughlin; J A Cooper; G A Davis; H Hassouna; J M Pivarnik; C J Womack
Journal:  Eur J Appl Physiol       Date:  2004-04-20       Impact factor: 3.078

Review 2.  Management of Deep Vein Thrombosis (DVT) Prophylaxis in Trauma Patients.

Authors:  Shahram Paydar; Golnar Sabetian; Hosseinali Khalili; Javad Fallahi; Mohammad Tahami; Bizhan Ziaian; Hamid Reza Abbasi; Shahram Bolandparvaz; Fariborz Ghaffarpasand; Zahra Ghahramani
Journal:  Bull Emerg Trauma       Date:  2016-01

3.  Bilateral upper-extremity deep vein thrombosis following central cord syndrome.

Authors:  Hilal Onmez; Havva Turac Cingoz; Sami Kucuksen; Emel Anliacık; Ozan Yaşar; Halim Yilmaz; Ali Salli
Journal:  J Spinal Cord Med       Date:  2013-05       Impact factor: 1.985

4.  Venous thromboembolism in acute spinal cord injury patients.

Authors:  Shyam K Saraf; Raj Jb Rana; Om P Sharma
Journal:  Indian J Orthop       Date:  2007-07       Impact factor: 1.251

5.  Bilateral humeral head osteonecrosis following spinal cord injury: a case report illustrating the importance of adhering to the recommendations of the Second National Acute Spinal Cord Injury Study.

Authors:  W R Osebold; M H Kody
Journal:  Iowa Orthop J       Date:  1994

6.  Deep vein thrombosis prophylaxis in trauma patients.

Authors:  Serdar Toker; David J Hak; Steven J Morgan
Journal:  Thrombosis       Date:  2011-05-15

7.  WACEM Consensus Paper on Deep Venous Thrombosis after Traumatic Spinal Cord Injury.

Authors:  Boris Vladimir Cabrera Nanclares; Huber Said Padilla-Zambrano; Ayman El-Menyar; Luis Rafael Moscote-Salazar; Sagar Galwankar; Ranabir Pal; Amrita Ghosh; Amit Agrawal; Mendoza-Flórez Romario
Journal:  J Emerg Trauma Shock       Date:  2019 Apr-Jun

8.  Usefulness of D-dimer and Ultrasonography Screening for Detecting Deep Vein Thrombosis in Patients with Spinal Cord Injury Undergoing Rehabilitation.

Authors:  Magdalena Mackiewicz-Milewska; Małgorzata Cisowska-Adamiak; Jerzy Pyskir; Iwona Świątkiewicz
Journal:  J Clin Med       Date:  2021-02-10       Impact factor: 4.241

9.  Effects of Four-Week Rehabilitation Program on Hemostasis Disorders in Patients with Spinal Cord Injury.

Authors:  Magdalena Mackiewicz-Milewska; Małgorzata Cisowska-Adamiak; Danuta Rość; Iwona Głowacka-Mrotek; Iwona Świątkiewicz
Journal:  J Clin Med       Date:  2020-06-12       Impact factor: 4.241

10.  A nested case-control study of risk for pulmonary embolism in the general trauma population using nationwide trauma registry data in Japan.

Authors:  Hiroki Iriyama; Akira Komori; Takako Kainoh; Yutaka Kondo; Toshio Naito; Toshikazu Abe
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.